Designing Antibiotics: Efflux Resistance Breaker Compounds and Activity Data

Mark Laws reports a novel antibiotic design strategy using fluoroquinolones as a model class. The dataset likely contains results for lead compounds KSN-L22 and BL-7, showing up to a 512-fold reduction in MIC against multidrug-resistant bacteria and activity in a murine infection model. The data was last updated on 2026-05-29.

Use Cases

• Training predictive models for antibiotic activity based on compound modifications described in the study.
• Analyzing structure-activity relationships for Efflux Resistance Breaker (ERB) modified fluoroquinolones.
• Benchmarking new compounds against the reported MIC90 values (0.03–2 μg/mL) across resistant bacterial strains.

Strengths

• Reports specific quantitative results, including a 512-fold reduction in MIC and IC50 values of ~3.8 μg/mL for DNA gyrase.
• Includes in vivo validation data from a murine thigh infection model showing a >4-log bacterial load reduction.
• Describes favorable pharmacokinetic and toxicity profiles, including absence of toxicity at 1200 mg/kg/day.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 457.1 KB, indicating limited scope.

Provenance

Source

figshare, author Mark Laws.

Collection Method

Likely contains experimental results from the described antibiotic design and testing study.

Freshness

Last updated 2026-05-29 04:48:37; freshness should be verified.